Bothell-based CMC Biologics, a manufacturer of therapeutic proteins, and Genexine, a disease-focused South Korean biotech company, recently entered a manufacturing agreement for Genexines’s next-generation, long-acting human growth hormone drug, GX-H9.

Genexine said it selected CMC Biologics as its partner due to the Bothell company’s technical expertise and high-quality operations.

“The successful transfer and manufacture of GX-H9 is critical to meeting our clinical timelines as we advance our lead candidate towards a pivotal study and we believe that CMC can take us there,” Genexine president and CEO Dr. Michael Keyoung said in a press release.

Human growth hormone is responsible for promoting the healthy growth and development of the human body. Genexine’s GX-H9 currently is being evaluated as a weekly and twice-monthly dosing regimen for treating Growth Hormone Deficiency in both adults and children.

“As human growth hormone plays a critical role in the human metabolic system, GX-H9 will be critical for both children and adults with hormone deficiency to receive this drug,” Gustavo Mahler, global chief executive officer and president of CMC Biologics said in a press release. “We are very excited to be working with Genexine, to help these patients potentially live their lives as normal as possible after treatment.”

Find Out First
Stay connected with the latest
Eastside business news.
no thanks